Our discovery of antigen-specific CD8+ T cell subsets and PD-1 expression in MS paves the way for identifying potential MS biomarkers and, more importantly, for exploring a novel treatment approach against this disease through intervention in the PD-1–PDL1 pathway. Here, PDCD1 is linked to myeloid sarcoma.